

**IN THE CLAIMS:**

Please amend claim 1 as follows:

- Q4
1. (Amended) A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO: 1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO: 2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO: 3); or direct equivalents thereof for use in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.

**IN THE ABSTRACT:**

Please replace the abstract at page 13 with the following rewritten abstract:

Q5

--Use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3), in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.--

**REMARKS**

The specification, claim 1 and abstract of the application have been amended to include sequence identification numbers for sequences described therein. Also enclosed are a paper copy and computer readable form of the Sequence Listing for amino acid sequences described in the application, a statement that the computer readable form is identical to the paper copy, a copy of the Notice To Comply With Sequence Requirements (mailed July 16, 2001) and a copy of the Cover Letter for Correction of Previous Notice (mailed July 16, 2001). Applicants respectfully request entry of the Sequence Listing into the application. No new matter has been added.


Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **"Version With Markings To Show Changes Made."**

In view of the foregoing, the application is now believed to be in proper form for allowance and notice to that effect is earnestly solicited.

If the Examiner believes a telephone conference would be of value, he/she is requested to call the undersigned at the number listed below.

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6938

  
\_\_\_\_\_  
Susan Hess  
Attorney for Applicants  
Reg. No. 37,350

Date: September 17, 2001

**"VERSION WITH MARKINGS TO SHOW CHANGES MADE."**

**IN THE SPECIFICATION:**

Please replace the paragraph beginning at page 1, line 8, with the following rewritten paragraph:

--More specifically, the present invention provides in a first aspect the use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1); said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3); or direct equivalents thereof in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.--

Please replace the paragraph beginning at page 2, line 1, with the following rewritten paragraph;

--a) a first domain comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3) and, b) a second domain comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence Ser-Ala-Ser-Ser-Ser-Ile-Ser-Tyr-Met-Gln (SEQ ID NO:4), said CDR2' having the amino acid sequence Asp-Thr-Ser-Lys-Leu-Ala-Ser (SEQ ID NO:5), and said CDR3' having the amino acid sequence His-Gln-Arg-Ser-Ser-Tyr-Thr (SEQ ID NO:6); or direct equivalents thereof.--

Please replace the paragraph beginning at page 3, line 1, with the following rewritten paragraph:

--the constant part or fragment thereof of a human heavy chain; said CDR1 having the amino acid sequence Arg-Tyr-Met-His (SEQ ID NO:1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3) and b) one immunoglobulin light chain or fragment thereof which comprises (i) a variable domain comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3' and (ii) the constant part or fragment thereof of a human light chain; said CDR1' having the amino acid sequence Ser-Ala-Ser-

Ser-Ser-Ile-Ser-Tyr-Met-Gln (SEQ ID NO:4), said CDR2' having the amino acid sequence Asp-Thr-Ser-Lys-Leu-Ala-Ser (SEQ ID NO:5), and said CDR3' having the amino acid sequence His-Gln-Arg-Ser-Ser-Tyr-Thr (SEQ ID NO:6) ; and direct equivalents thereof.—

Please insert the paper copy of the attached Sequence Listing after page 10 and before the Claims and renumber the pages of the application.

**IN THE CLAIMS:**

Please amend claim 1 as follows:

1. (Amended) A CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO: 1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO: 2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO: 3); or direct equivalents thereof for use in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.

**IN THE ABSTRACT:**

Please replace the abstract at page 13 with the following rewritten abstract;

--Use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1), said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe (SEQ ID NO:3), in the treatment of rheumatoid arthritis or inflammatory or hyperproliferative skin diseases.--